Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice

Vaccine

Volumn 29, Issue 44, 2011, Pages 7624-7630

  Wu, Juan ^a,b   Ma, Hui ^a   Qu, Qing ^a   Zhou, Wen Jiang ^a   Luo, Yu Ping ^b   Thangaraj, Harry ^c   Lowrie, Dougtas B ^a   Fan, Xiao Yong ^a  

^a SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^b NANCHANG UNIVERSITY   (China)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CpG motif; DNA treatment; DNA vaccine; DsRNAs; Mycobacterium tuberculosis; Th1 immnue response

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD86 ANTIGEN; DNA VACCINE; DOUBLE STRANDED RNA; GAMMA INTERFERON; HEAT SHOCK PROTEIN 65; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; MESSENGER RNA; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL GENE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA FLANKING REGION; DOWNSTREAM PROCESSING; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VIVO STUDY; MAMMAL CELL; MOUSE; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN MOTIF; TH1 CELL; THERAPY EFFECT;

AMINO ACID MOTIFS; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, CD80; ANTIGENS, CD86; BACTERIAL LOAD; BACTERIAL PROTEINS; CELL LINE; CHAPERONIN 60; CYTOKINES; GENE EXPRESSION; GENE EXPRESSION PROFILING; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; LUNG; MACROPHAGES; MICE; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; PLASMIDS; SPLEEN; TH1 CELLS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 80053610412     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.020     Document Type: Article

References (44)

1. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
2. Mor G., Klinman D.M., Shapiro S., Hagiwara E., Sedegah M., Norman J.A., et al. Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J Immunol 1995, 155:2039-2046.
3. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M.D., et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273:352-354.
4. Stacey K.J., Sweet M.J., Hume D.A. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996, 157:2116-2122.
5. Pisetsky D.S. Immune activation by bacterial DNA: a new genetic code. Immunity 1996, 5:303-310.
6. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 1997, 27:2340-2344.
7. Yamamoto S., Yamamoto T., Tokunaga T. The discovery of immunostimulatory DNA sequence. Springer Semin Immunopathol 2000, 22:11-19.
8. Klinman D.M., Klaschik S., Tomaru K., Shirota H., Tross D., Ikeuchi H. Immunostimulatory CpG oligonucleotides: effect on gene expression and utility as vaccine adjuvants. Vaccine 2010, 28:1919-1923.
9. Liu F.Y., Shang J.L., Song S.X., Zheng L., Zhang K.X., You H.Y., et al. Augmented induction of antigen-specific cytotoxic T cell responses against canine hepatitis by co-immunization with pVAX1-CpG-loop and adjuvants in BALB/c mice. Exp Anim 2010, 59:579-588.
10. Klinman D.M., Klaschik S., Sato T., Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009, 61:248-255.
11. Wagner H. The immunogenicity of CpG-antigen conjugates. Adv Drug Deliv Rev 2009, 61:243-247.
12. da Fonseca D.M., Silva C.L., Wowk P.F., Paula M.O.E., Ramos S.G., Horn C., et al. Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion. Infect Immun 2009, 77:5311-5321.
13. Dorn A., Kippenberger S. Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. Curr Opin Mol Ther 2008, 10:10-20.
14. Gill D.R., Pringle I.A., Hyde S.C. Progress and prospects: the design and production of plasmid vectors. Gene Ther 2009, 16:165-171.
15. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
16. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
17. Sugiyama T., Gursel M., Takeshita F., Cohan C., Conover J., Kaisho T., et al. CpG RNA: identification of novel single-stranded RNA that stimulates human CD14(+)CD11c(+) monocytes. J Immunol 2005, 174:2273-2279.
18. Ablasser A., Poeck H., Anz D., Berger M., Schlee M., Kim S., et al. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol 2009, 182:6824-6833.
19. Berger M., Ablasser A., Kim S., Bekerejian-Ding I., Giese T., Endres S., et al. TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA. J Immunother 2009, 32:262-271.
20. Koyama S., Coban C., Aoshi T., Horii T., Akira S., Ishii K.J. Innate immune control of nucleic acid-based vaccine immunogenicity. Expert Rev Vaccines 2009, 8:1099-1107.
21. Ishii K.J., Akira S. Innate immune recognition of, and regulation by, DNA. Trends Immunol 2006, 27:525-532.
22. Ishii K.J., Akira S. Innate immune recognition of nucleic acids: beyond toll-like receptors. Int J Cancer 2005, 117:517-523.
23. Tovey M.G., Lallemand C., Meritet J.F., Maury C. Adjuvant activity of interferon alpha: mechanism(s) of action. Vaccine 2006, 24:S46-S47.
24. Trinchieri G. Type I interferon: friend or foe?. J Exp Med 2010, 207:2053-2063.
25. Perry A.K., Chen G., Zheng D.H., Tang H., Cheng G.H. The host type I interferon response to viral and bacterial infections. Cell Res 2005, 15:407-422.
26. Hamilton M.J., Antignano F., von Rossum A., Boucher J.L., Bennewith K.L., Krystal G. TLR agonists that induce IFN-beta abrogate resident macrophage suppression of T cells. J Immunol 2010, 185:4545-4553.
27. Kaufmann S.H., Andersen P. Immunity to mycobacteria with emphasis on tuberculosis: implications for rational design of an effective tuberculosis vaccine. Chem Immunol 1998, 70:21-59.
28. Andersen P. TB vaccines: progress and problems. Trends Immunol 2001, 22(3):160-168.
29. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993, 178(6):2243-2247.
30. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993, 178(6):2249-2254.
31. Tascon R.E., Colston M.J., Ragno S., Stavropoulos E., Gregory D., Lowrie D.B. Vaccination against tuberculosis by DNA injection. Nat Med 1996, 2:888-892.
32. Okada M., Kita Y., Nakajima T., Kanamaru N., Hashimoto S., Nagasawa T., et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. Vaccine 2007, 25:2990-2993.
33. Skinner M.A., Wedlock D.N., de Lisle G.W., Cooke M.M., Tascon R.E., Ferraz J.C., et al. The order of prime-boost vaccination of neonatal calves with Mycobacterium bovis BCG and a DNA vaccine encoding mycobacterial proteins Hsp65 Hsp70, and Apa is not critical for enhancing protection against bovine tuberculosis. Infect Immun 2005, 73:4441-4444.
34. Shi C., Yuan S., Zhang H., Zhang T., Wang L., Xu Z. Cell-mediated immune responses and protective efficacy against infection with Mycobacterium tuberculosis induced by Hsp65 and hIL-2 fusion protein in mice. Scand J Immunol 2009, 69:140-149.
35. Lowrie D.B., Tascon R.E., Bonato V.L., Lima V.M., Faccioli L.H., Stavropoulos E., et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999, 400:269-271.
36. Lowrie D.B. DNA vaccines for therapy of tuberculosis: where are we now?. Vaccine 2006, 24:1983-1989.
37. Torrado E., Cooper A.M. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev 2010, 21(6):455-462.
38. Peck A., Mellins E.D. Precarious balance: Th17 cells in host defense. Infect Immun 2010, 78(1):32-38.
39. Lin Y.Y, Slight S.R., Khader S.A. Th17 cytokines and vaccine-induced immunity. Semin Immunopathol 2010, 32(1):79-90.
40. Tanaka J., Watanabe N., Kido M., Saga K., Akamatsu T., Nishio A., et al. Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions. Clin Exp Allergy 2009, 39(1):89-100.
41. Yoneyama M., Fujita T. Recognition of viral nucleic acids in innate immunity. Rev Med Virol 2010, 20:4-22.
42. Nakhaei P., Genin P., Civas A., Hiscott J. RIG-I-like receptors: sensing and responding to RNA virus infection. Semin Immunol 2009, 21:215-222.
43. Schmidt A., Schwerd T., Hamm W., Hellmuth J.C., Cui S., Wenzel M., et al. 5'-Triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci USA 2009, 106:12067-12072.
44. Li X.J., Lu C., Stewart M., Xu H.Y., Strong R.K., Igumenova T., et al. Structural basis of double-stranded RNA recognition by the RIG-I like receptor MDA5. Arch Biochem Biophys 2009, 488:23-33.